Fourchette de valorisation composite · prudent $68–$74 / raisonnable $110–$148 / optimiste $202–$220. À $167.98, Entre la fourchette raisonnable et la fourchette optimiste.
À la publication $170.77 (2 juillet 2026)
UnitedHealth will cover Guardant's Shield colorectal cancer blood test for about 40 million members.
Possible impact:May affect Shield adoption, screening revenue expectations, and market penetration assumptions.
The American Cancer Society added Shield as a colorectal cancer screening option for people aged 50 and older.
Possible impact:May influence physician adoption, commercial reimbursement odds, and screening growth expectations.
Guardant won FDA approval for its newer Guardant360 Liquid CDx blood-based cancer test.
Possible impact:May affect therapy-selection test volume, pricing, and 2027 revenue acceleration expectations.
Guardant's Q1 revenue rose 48% to $301.7 million, and it raised 2026 revenue guidance.
Possible impact:May affect views on growth durability, loss narrowing, and full-year revenue expectations.
Guardant Health plans to launch a blood-based multi-cancer detection test in India with Zydus Lifesciences.
Possible impact:May affect expectations for international expansion and long-term screening-test market opportunity.
Automatically summarized from public sources; for context only, not investment advice.
Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Pas encore d'analyse sur cette valeur dans votre langue.
